Drugs / Anrotinib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05981157 | Jun 2023 → Dec 2025 | nasopharyngeal carcinoma | Zhongshan People's Hospital, Guangdong, China | Unknown | No outcome recorded |
| Phase 2 | NCT05683704 | Sep 2022 → May 2024 | classic Hodgkin lymphoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05747521 | Apr 2021 → Sep 2024 | soft tissue sarcoma | Henan Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anrotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05747521 ↗ |
| Route | Oral | “Anrotinib administered PO at day 1-14 every 3 weeks” NCT05683704 ↗ |